Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.

McElroy SL, Guerdjikova AI, Blom TJ, Mori N, Romo-Nava F

Journal of clinical psychopharmacology15 Jan 2024Cited by 25 (Europe PMC)

PMID38227621DOI10.1097/jcp.0000000000001803PepBankPUB-38227621

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with stable bipolar disorder and obesity or overweight, liraglutide gave a significantly greater reduction in percent body weight than placebo.
In plain wordsIn people with stable bipolar disorder and excess weight, liraglutide reduced body weight percentage more than placebo.
Peptide
Liraglutide
Outcome
DecreasePercent change in body weight
Study
n = 60
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg/d (target) · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide was associated with significantly greater reductions in percent change in body weight
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 40-week, randomized (1:1 ratio), placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide targeted to 3.0 mg/d (in combination with a reduced-calorie diet and increased physical activity) in 60 participants with stable BD who were obese or overweight.
Report a problemFND-3822762101
02HumanRandomized controlled trialEfficacy outcome
In adults with stable bipolar disorder and obesity or overweight, a significantly greater percentage of participants lost at least 5% of body weight with liraglutide than with placebo.
In plain wordsIn people with stable bipolar disorder and excess weight, more people lost at least 5% of body weight with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseParticipants who lost at least 5% of body weight
Study
n = 60
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg/d (target) · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide was associated with significantly greater reductions in percent change in body weight, percentage of participants who lost at least 5% of body weight
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 40-week, randomized (1:1 ratio), placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide targeted to 3.0 mg/d (in combination with a reduced-calorie diet and increased physical activity) in 60 participants with stable BD who were obese or overweight.
Report a problemFND-3822762102
03HumanRandomized controlled trialEfficacy outcome
In adults with stable bipolar disorder and obesity or overweight, liraglutide gave significantly greater reductions in hemoglobin A1c than placebo.
In plain wordsIn people with stable bipolar disorder and excess weight, liraglutide lowered hemoglobin A1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHemoglobin A1c
Study
n = 60
Comparator
Placebo
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg/d (target) · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide was associated with significantly greater reductions in percent change in body weight, percentage of participants who lost at least 5% of body weight, and reductions in weight, BMI, hemoglobin A 1c levels, binge eating, and hunger.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 40-week, randomized (1:1 ratio), placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide targeted to 3.0 mg/d (in combination with a reduced-calorie diet and increased physical activity) in 60 participants with stable BD who were obese or overweight.
Report a problemFND-3822762105
04HumanRandomized controlled trialEfficacy outcome
In adults with stable bipolar disorder and obesity or overweight, liraglutide gave significantly greater reductions in binge eating than placebo.
In plain wordsIn people with stable bipolar disorder and excess weight, liraglutide reduced binge eating more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBinge eating
Study
n = 60
Comparator
Placebo
Analysis
Secondary
Outcome group
Appetite and food intake · Mental health and mood
Studied dose
3.0 mg/d (target) · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide was associated with significantly greater reductions in percent change in body weight, percentage of participants who lost at least 5% of body weight, and reductions in weight, BMI, hemoglobin A 1c levels, binge eating, and hunger.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 40-week, randomized (1:1 ratio), placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide targeted to 3.0 mg/d (in combination with a reduced-calorie diet and increased physical activity) in 60 participants with stable BD who were obese or overweight.
Report a problemFND-3822762106
05HumanRandomized controlled trialEfficacy outcome
In adults with stable bipolar disorder and obesity or overweight, liraglutide gave significantly greater reductions in hunger than placebo.
In plain wordsIn people with stable bipolar disorder and excess weight, liraglutide reduced hunger more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHunger
Study
n = 60
Comparator
Placebo
Analysis
Secondary
Outcome group
Appetite and food intake · Mental health and mood
Studied dose
3.0 mg/d (target) · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide was associated with significantly greater reductions in percent change in body weight, percentage of participants who lost at least 5% of body weight, and reductions in weight, BMI, hemoglobin A 1c levels, binge eating, and hunger.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 40-week, randomized (1:1 ratio), placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide targeted to 3.0 mg/d (in combination with a reduced-calorie diet and increased physical activity) in 60 participants with stable BD who were obese or overweight.
Report a problemFND-3822762107
06HumanRandomized controlled trialEfficacy outcome
In adults with stable bipolar disorder and obesity or overweight, liraglutide gave significantly greater reductions in weight than placebo.
In plain wordsIn people with stable bipolar disorder and excess weight, liraglutide reduced weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseWeight reduction
Study
n = 60
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg/d (target) · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide was associated with significantly greater reductions in percent change in body weight, percentage of participants who lost at least 5% of body weight, and reductions in weight, BMI, hemoglobin A 1c levels, binge eating, and hunger.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 40-week, randomized (1:1 ratio), placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide targeted to 3.0 mg/d (in combination with a reduced-calorie diet and increased physical activity) in 60 participants with stable BD who were obese or overweight.
Report a problemFND-3822762103
07HumanRandomized controlled trialEfficacy outcome
In adults with stable bipolar disorder and obesity or overweight, liraglutide gave significantly greater reductions in BMI than placebo.
In plain wordsIn people with stable bipolar disorder and excess weight, liraglutide reduced BMI more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n = 60
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg/d (target) · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide was associated with significantly greater reductions in percent change in body weight, percentage of participants who lost at least 5% of body weight, and reductions in weight, BMI, hemoglobin A 1c levels, binge eating, and hunger.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 40-week, randomized (1:1 ratio), placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide targeted to 3.0 mg/d (in combination with a reduced-calorie diet and increased physical activity) in 60 participants with stable BD who were obese or overweight.
Report a problemFND-3822762104
08HumanRandomized controlled trialSafety outcome
In adults with stable bipolar disorder and obesity or overweight, liraglutide was reported as well tolerated.
In plain wordsIn people with stable bipolar disorder and excess weight, liraglutide was reported as well tolerated.
Peptide
Liraglutide
Outcome
Not applicableTolerability
Study
n = 60
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
3.0 mg/d (target) · 40 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide was well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a 40-week, randomized (1:1 ratio), placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide targeted to 3.0 mg/d (in combination with a reduced-calorie diet and increased physical activity) in 60 participants with stable BD who were obese or overweight.
Report a problemFND-3822762108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT03158805

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Lindner Center of HOPEn = 6026 Apr 2017 to 1 Jan 2023

Bipolar Disorder · Obesity

Trial page ClinicalTrials.govUpdated 12 Mar 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.